Drug Interactions between pemivibart and sars-cov-2 (covid-19) ad26 vaccine, recombinant

ADJUST DOSING INTERVAL: The administration of pemivibart within two weeks after receiving a SARS-CoV-2 (COVID-19) vaccine may be associated with a diminished or suboptimal immunologic response to the vaccine. The mechanism of this interaction has not been fully described in product labeling. Pemivibart exerts its effects by binding to the virus' spike protein receptor binding domain (RBD) thereby inhibiting virus attachment to the human ACE2 receptor on host cells. Therefore, it may also bind to the viral spike protein introduced by a COVID-19 vaccine, potentially interfering with the vaccine's ability to mount an adequate immune response. The timing of COVID-19 vaccination following the receipt of pemivibart is not discussed in product labeling. However, the U.S. Centers for Disease Control and Prevention (CDC) advises that people who are moderately or severely immunocompromised should receive the COVID-19 vaccination according to the recommended schedule. Clinical data surrounding a loss of efficacy of the COVID-19 vaccine if given prior to, or after pemivibart administration are not available.

MANAGEMENT: Pemivibart should be administered at least 2 weeks after the receipt of a COVID-19 vaccination to avoid the potential loss of vaccine efficacy. Additionally, current immunization guidelines for people who are moderately or severely immunocompromised recommend that COVID-19 vaccination be given in accordance with the recommended vaccine schedule, and pemivibart not be given as a substitution for COVID-19 vaccination.